thetaOwl
HomeOptionsABUSGreeks

ABUS

Arbutus Biopharma CorporationClose $4.37EOD only
Max Pain
$4.00
Next expiry Jun 18, 2026
Expected Move
±$0.62
14.3% from close
Price Gap
-0.37
Distance to max pain
IV Rank
14
Low premium
P/C OI
0.91
Balanced positioning
Consensus
—
No reports available
Published snapshot: May 20, 2026 close
End-of-day snapshot

This page reflects ABUS options positioning from the latest published market-close snapshot. Intraday price and contract changes are not displayed.

Published Snapshot
May 20, 2026 close
Greeks — ABUS
Data as of market close May 20, 2026

Chart-first surface for GEX/DEX positioning, with compact context stats.

ABUS Greeks Data

Total GEX
$-0.00B
Total DEX
$0.7M
Spot Price
$4.37

Gamma Exposure (GEX)

Delta Exposure (DEX)

Strike Concentration
Primary Wall
$4.00
DEX Cluster
$4.00
About This Data
Built from the latest end-of-day options snapshot to help frame dealer positioning.
What this view measures

GEX and DEX are aggregate dealer-exposure estimates derived from the end-of-day options chain. They are context tools for positioning, not live per-contract greeks.

How traders usually read it

Positive GEX can point to more dampened price action, while negative GEX can make breaks more reactive. DEX helps flag whether hedge pressure leans more directional.

What to keep in mind

Vanna and charm can shift quickly as spot moves and time decays, so use walls and clusters as reference zones rather than hard support or resistance.

Need the full methodology? See how ThetaOwl calculates GEX, DEX, and related analytics.